. " "@en . "LD₅₀=300 mk/kg (Oral in mice); LD₅₀=791 mg/kg (Oral in rats); LD₅₀=87 mk/kg (IV in mice); LD₅₀=37 mg/kg (IV in rats)"@en . . . . . . "Fairly slow and incomplete after oral administration"@en . . "Humans and other mammals"@en . . . . . "Flupenthixol is a thioxanthene antipsychotic. The mechanism of action of Flupenthixol is not completely understood. Flupenthixol is a powerful antagonist of both D1 and D2 dopamine receptors, and an alpha-adrenergic receptor antagonist. It's antipsychotic activity is thought to be related to blocks postsynaptic dopamine receptors in the CNS."@en . . . "Take with food to reduce irritation."@en . "Flupentixol"@en . . . . . . "Flupentixolo"@en . . "Smith Kline & French Laboratories; British Patent 925,538; May 8, 1963. Craig, P.N. and Zirkle, C.L.; U.S. Patent 3,282,930; November 1, 1966; assigned to Smith Kline & French Laboratories."@en . . . . . " "@en . "19 to 39 hours"@en . "Highly bound to plasma proteins (>95%)"@en . "For use in the treatment of schizophrenia and depression"@en . "Flupentixolum"@en . "Avoid alcohol."@en . . "approved"@en . . . . . "Flupenthixole"@en . "Flupentixol"@en . . . . . "Flupenthixol"@en . . . . . "Flupentixol is an antipsychotic neuroleptic drug. It is a thioxanthene, and therefore closely related to the phenothiazines. Its primary use is as a long acting injection given two or three weekly to people with schizophrenia who have a poor compliance with medication and suffer frequent relapses of illness. It is a D1 and D2 receptor antagonist. It is not approved in the United States. "@en . . . . . . . . . . . . "withdrawn"@en . . "2709-56-0"@en . . .